Veracyte, Inc. (VCYT) — Analysis Summary
Veracyte, Inc. (VCYT) has a market cap of $3.54B with year-over-year revenue growth of +16.0%. Net margin stands at 12.8%. The stock trades at a P/E ratio of 30.9.
Key Takeaways
- Revenue changed +16.0% year-over-year
- Net margin of 12.8%
- P/E ratio of 30.9
Compared to other companies in the SERVICES-MEDICAL LABORATORIES sector, VCYT posted revenue growth of +16.0% and trades at a P/E of 30.9.
Veracyte, Inc. (VCYT)
PREVIOUS CLOSE 2026-10-12 · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsNo Major Flags
No major credit, margin, or trend red flags were triggered from the latest filings.
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).
Sector
SERVICES-MEDICAL LABORATORIES
Employees
755
Headquarters
SOUTH SAN FRANCISCO, CA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.